From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development

Drug companies and government research agencies in many other countries are enhancing their positions on the biotech playing field, building their own educational and technological infrastructures, and in some case creating vast new biotech research districts or complexes. Not surprisingly, countries such as India, Singapore and China, which have already made deep inroads into other technology-based industries, are investing in major efforts in biotechnology, which is very much an information-based science. Firms that manufacture generics and provide contract research, development and clinical trials services are already common in such nations. In most cases, this was just a beginning, with original drug and technology development a rapidly evolving, symbiotic industry.

The government of Singapore, for example, has made biotechnology one of its top priorities for development, vowing to make it one of the staples of its economy. Its “Biopolis” research and development center opened in 2003. Biopolis is part of a master planned science and technology park called One-North. The complex is recognized as a center for stem cell and cell therapy research. It is a melting pot of scientists and corporations from all over the world, attracted to Singapore’s central location, direct airline access to all of the world’s major cities and status as a highly respected health care center with a well-educated, largely English-speaking population. For example, the Novartis Institute for Tropical Diseases at Singapore has more than 100 researchers from 18 different nations. Biopolis was built in five phases at an estimated cost of $700 million. Phase I encompasses 1.99 million square feet and opened in 2003. Phase II added two seven-story buildings (398,268 square feet total) and opened in 2006. Phase III, completed in 2011, includes more than 400,000 square feet of laboratories, research facilities, office and retail space. Phases IV and V, adding additional space for research and clinical trials, were completed in 2013. (Another unit of the One-North development is called Fusionopolis, a 24-story building housing researchers, designers and entrepreneurs in media, software, communications and entertainment.)

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Become a Plunkett Research Online subscriber to gain unlimited access to our massive amount of vital industry data and market research.

✔ 100,000 Industry Statistics
✔ 500 Industries Analyzed for Market Size, Profits and Forecasts
✔ 150,000 Industry Executives Profiled
✔ 25,000 Companies Profiled, Ranked and Analyzed
✔ 1,000 Vital Trends Analyzed, totaling 1,000,000 words

Learn More

From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development, Business and Industry Trends Analysis

A Representative List of Organizations that Have Used our Research and Products:

How to access Plunkett Research data.

What data challenge can we help you solve today?

Take a Tour

Contact

Testimonials